Proactive Investors - Run By Investors For Investors

Genedrive’s Hep C diagnostic device excels in African performance study

Africa is host to a wider variety of genomes than Europe, so Genedrive wanted to make sure its HCV ID Kit still worked well
genedrive hcv id kit
The test could tell, with 100% accuracy, whether or not a sample was infected with the virus

Genedrive PLC’s (LON:GDR) Hepatitis C (HCV) ID Kit has undergone more rigorous and successful testing – this time in Africa.

The handheld device which detects the virus was put through its paces by scientists at a testing laboratory in Johannesburg, South Africa.

READ: Handheld diagnostics specialist genedrive confirms award of £600,000 grant

AIM-listed Genedrive wanted to show that its HCV ID Kit would work just as well across the diverse genotypes which are prevalent in Africa compared to Europe.

In a cohort of 130 clinical samples from several sub-Saharan countries including South Africa, Kenya and Ghana, the device demonstrated sensitivity and specificity of 100%.

In layman’s terms, that means the HCV ID Kit correctly identified samples with the disease as well as correctly identifying those without.

On top of that, the scientists also found the device easy to operate which, compared to the Abbott M2000 platform, required no maintenance and had faster processing times.

"These positive results with the genedrive HCV assay in customer hands on local samples confirms that our good clinical validation performance can be translated into real-world settings where the test will be used,” said chief executive David Budd.

“We remain confident it can play an important role in the diagnosis and management of the disease in Africa and in other territories where access to centralized laboratories is limited.”

Towards the end of 2017, Genedrive signed a distribution agreement with Sysmex which will see the latter market and sell the HCV ID Kit and Genedrive platform in the EMEA region, with an initial focus on Africa.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use